NurExone Biologic Demonstrates Its Patent-Pending Platform Technology for Loading Exosomes with Therapeutic Molecules

On November 30, 2022, NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, reported results of a pre-clinical loading efficiency study that was completed by the Company showing that its innovative and proprietary loading technology has the potential to serve as an efficient process for loading of therapeutic molecular cargo into exosomes. In exosome-based therapies, loaded exosomes are biologically guided to target inflamed tissues to "dock" and unload their therapeutic cargo, creating a healing environment.

Login Or Register To Read Full Story